Medwatch sent to fda on 12/28/2016.The reporter of the event was asked to return the product for analysis.To date, apollo has not received the device.Device labeling addresses the reported events as follows: warnings and precautions: the physiological response of the patient to the presence of the orbera system balloon may vary depending upon the patient's general condition and the level and type of activity.The types and frequency of administration of drugs or diet supplements and the overall diet of the patient may also affect the response.Each patient must be monitored closely during the entire term of treatment in order to detect the development of possible complications.Complications: gastric discomfort, feelings of nausea and vomiting following balloon placement as the digestive system adjusts to the presence of the balloon.Continuing nausea and vomiting.This could result from direct irritation of the lining of the stomach or as a result of the balloon blocking the outlet of the stomach.It is even theoretically possible that the balloon could prevent vomiting (not nausea or retching) by blocking the inlet to the stomach from the esophagus.
|
Device evaluation summary: the device was returned to the apollo device analysis laboratory.A visual examination was performed on the device, and noted blue discoloration on the shell.Yellow particles were observed on the outer surface of the shell, patch and valve.A valve test was performed and the flow of di water was continuous and unobstructed.An air leak test was performed and leakage was observed.Under microscopic analysis, thirteen small striated openings and one large striated opening, 5 mm in length were observed, all consistent with device removal activities.Yellow and brown particles were observed in the valve channel.
|